Mechanisms of drug resistance to gefifinib and erlotinib
10.3760/cma.j.issn.1673-422X.2010.10.005
- VernacularTitle:吉非替尼和厄洛替尼耐药机制
- Author:
Lin LIN
- Publication Type:Journal Article
- Keywords:
Receptor,epidermal growth factor;
Carcinoma,non-small-cell lung;
Drug resistance,neoplasm
- From:
Journal of International Oncology
2010;37(10):734-736
- CountryChina
- Language:Chinese
-
Abstract:
Gefitinib and erlotinib are the first generation of targeted therapeutic agents approved for the treatment of advanced non-small cell lung cancer. Despite a dramatic initial response, most patients subsequently and ultimately become resistant to the drugs. Recent studies have proposed various mechanisms of such resistance, some of which related to a second mutation in epidermal growth factor receptor, aberrant activation of other tyrosine kinase receptors, bypassing signal pathways and constitutive activation of downstream signal molecules. Other researches also associated the drug resistance to internalization of epidermal growth factor receptor and changes in tumor microenvironment. Furture studies need to focus on overcoming or reversing resistance to the drugs and developing new targeted therapeutic agents.
